Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies. It has a wide range of technologies, including molecular antibody screening, construction of high-yield stable CHO cell lines and therapeutic antibody analysis and detection. As of the date of this prospectus, a total of 6 drugs have been formally established and are in the research and development stage, and the two drugs which are currently in rapid progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002).
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM